Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents

Steve D Wilton
Sue Fletcher
Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Crawley, Perth, WA, Australia

Abstract: The identification of dystrophin and the causative role of mutations in this gene in Duchenne and Becker muscular dystrophies (D/BMD) was expected to lead to timely development of effective therapies. Despite over 20 years of research, corticosteroids remain the only available pharmacological treatment for DMD, although significant benefits and extended life have resulted from advances in the clinical care and management of DMD individuals. Effective treatment of DMD will require dystrophin restitution in skeletal, cardiac, and smooth muscles and nonmuscle tissues; however, modulation of muscle loss and regeneration has the potential to play an important role in altering the natural history of DMD, particularly in combination with other treatments. Emerging biological, molecular, and small molecule therapeutics are showing promise in ameliorating this devastating disease, and it is anticipated that regulatory environments will need to display some flexibility in order to accommodate the new treatment paradigms.

Keywords: Duchenne muscular dystrophy, molecular therapeutics, small molecules

Background
Duchenne muscular dystrophy (DMD), an X-linked recessive condition caused by mutations in the huge dystrophin gene, is the most common and serious form of childhood muscle wasting, with an incidence of 1 in 3500 live male births (for review see Emery \(^1\)). Under tissue-specific control of at least seven promoters, the full-length 427 kDa dystrophin isoforms, encoded by 79 exons spanning ~2.4 Mbp, are expressed primarily in skeletal, cardiac, and smooth muscles and brain (for review see Love et al \(^2\)). The prevalence of DMD may be attributed to the high frequency of de novo mutations, which in turn is influenced by the size, nature, and organization of the dystrophin gene. Many dystrophin introns are fivefold to eightfold larger than the average human gene of 30 kb pairs. One in three cases of DMD present with no prior family history, \(^3\) and this fact, coupled with the size and complexity of the gene pose great challenges to prevention and genetic counseling programs.

In 1986/1987, mutations in the dystrophin gene were identified as causing DMD, and it became apparent that protein-truncating defects led to the severe form of muscle wasting, while in-frame deletions were often associated with a milder, less progressive form of muscle wasting, Becker muscular dystrophy (BMD). \(^4\)–\(^6\) Dystrophin gene replacement therapy became a possibility, but the size, nature, and widespread expression in skeletal muscle were soon recognized as major challenges. The reading frame hypothesis proposed by Monaco et al \(^6\) holds true in the majority of cases,
although there are some exceptions, now explained by altered gene transcript processing. More importantly, the reading frame rule offered two potential avenues for therapy: 1) Insert the dystrophin-coding sequence from mildly affected/asymptomatic BMD patients into viral vectors and exploit these smaller payloads. 2) Modify expression of the dystrophin gene to remove or bypass DMD-causing mutations so that a functional BMD-like dystrophin isoform is produced. This review will focus on novel therapeutic compounds invoking avenues of intervention to either restore or supplement dystrophin and some of the potential treatments designed to modulate muscle pathology in DMD (Table 1). Each strategy offers different targets for intervention and some may be complementary, thereby providing additional possibilities for therapeutic benefit. The greatest benefit to patients is likely to be derived from dystrophin restitution; however, not all DMD mutations will be amenable to molecular interventions, and for some individuals, therapies that reduce muscle pathology may provide at least interim benefits. We will first consider potential treatments designed to modulate pathogenic processes arising from the loss of the functional 427-kDa dystrophin isoform and then discuss nonviral approaches

Table 1 Ready-to-use, indirect, and dystrophin-restitution ‘molecular’ therapy clinical trials for DMD listed at http://clinicaltrials.gov

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Completion</th>
<th>Phase</th>
<th>Status</th>
<th>ClinicalTrials.gov identifier and supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ready-to-use/indirect therapies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomized study of daily vs high-dose weekly prednisone therapy in DMD</td>
<td>December 2007</td>
<td>2/3</td>
<td>Completed</td>
<td>NCT00110669</td>
</tr>
<tr>
<td>Clinical trial of coenzyme Q10 and lisinopril in muscular dystrophies</td>
<td>December 2013</td>
<td>2/3</td>
<td>Recruiting</td>
<td>NCT012669710,11</td>
</tr>
<tr>
<td>Tadalafil in BMD</td>
<td>December 2012</td>
<td>4</td>
<td>Recruiting</td>
<td>NCT0107051112</td>
</tr>
<tr>
<td>IGF-1 therapy and muscle function in DMD</td>
<td>November 2011</td>
<td>1/2</td>
<td>Recruiting</td>
<td>NCT01270908</td>
</tr>
<tr>
<td>Sunphenon epigallocatechin-gallate in DMD</td>
<td>September 2012</td>
<td>2/3</td>
<td>Recruiting</td>
<td>NCT01183767</td>
</tr>
<tr>
<td>Long-term safety, tolerability, and efficacy of idebenone in DMD (DELPHI extension)</td>
<td>February 2011</td>
<td>2</td>
<td>Active, not yet recruiting</td>
<td>NCT00758225</td>
</tr>
<tr>
<td>Extension study of ACE-031 in subjects with DMD</td>
<td>December 2012</td>
<td>2</td>
<td>Recruiting by invitation</td>
<td>NCT0123975813</td>
</tr>
<tr>
<td>Study of ACE-031 in subjects with DMD</td>
<td>February 2012</td>
<td>2</td>
<td>Recruiting</td>
<td>NCT0109976113</td>
</tr>
<tr>
<td>Phase III study of idebenone in DMD</td>
<td>December 2011</td>
<td>3</td>
<td>Recruiting</td>
<td>NCT01027884</td>
</tr>
<tr>
<td><strong>Molecular therapies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dystrophin restitution: stop codon read-through</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Phase IIa extension study of PTC124 in DMD</td>
<td>March 2011</td>
<td>2a</td>
<td>Terminated</td>
<td>NCT0075987614–17</td>
</tr>
<tr>
<td>A Phase IIa study of ataluren (PTC124) in nonambulatory patients with nonsense-mutation-mediated D/BMD</td>
<td>June 2011</td>
<td>–</td>
<td>Suspended</td>
<td>NCT0100929414–17</td>
</tr>
<tr>
<td>Phase IIb study of PTC124 in D/BMD</td>
<td>December 2009</td>
<td>2/3</td>
<td>Completed</td>
<td>NCT0059255314–17</td>
</tr>
<tr>
<td>Phase IIb extension study of ataluren (PTC124) in D/BMD</td>
<td>December 2011</td>
<td>2/3</td>
<td>Terminated</td>
<td>NCT0084737914–17</td>
</tr>
<tr>
<td>Study of ataluren for previously treated patients with nmDBMD in the United States</td>
<td>July 2012</td>
<td>3</td>
<td>Recruiting</td>
<td>NCT01247207</td>
</tr>
<tr>
<td>Six month study of gentamicin in DMD with stop codons</td>
<td>July 2009</td>
<td>1</td>
<td>Completed</td>
<td>NCT0045107418</td>
</tr>
<tr>
<td><strong>Dystrophin restitution: exon skipping</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A clinical study to assess the efficacy and safety of GSK2402968 in subjects with DMD</td>
<td>March 2011</td>
<td>3</td>
<td>Not yet recruiting</td>
<td>NCT01254019</td>
</tr>
<tr>
<td>Phase II double-blind exploratory study of GSK2402968 in ambulant subjects with DMD</td>
<td>November 2011</td>
<td>2</td>
<td>Recruiting</td>
<td>NCT01153932</td>
</tr>
<tr>
<td>A double-blind, escalating dose, randomized, placebo-controlled study to assess the pharmacokinetics, safety, and tolerability of single subcutaneous injections of GSK2402968 in nonambulant subjects with DMD</td>
<td>January 2011</td>
<td>1</td>
<td>Recruiting</td>
<td>NCT01128855</td>
</tr>
<tr>
<td>Phase I/II study of PRO044 in DMD</td>
<td>September 2011</td>
<td>1/2</td>
<td>Recruiting</td>
<td>NCT0103730919</td>
</tr>
<tr>
<td>Restoring dystrophin expression in DMD: a phase I/II clinical trial using AVI-4658</td>
<td>March 2009</td>
<td>1/2</td>
<td>Completed</td>
<td>NCT0015925020</td>
</tr>
<tr>
<td>Dose-ranging study of AVI-4658 to induce dystrophin expression in selected DMD patients</td>
<td>June 2010</td>
<td>1/2</td>
<td>Ongoing</td>
<td>NCT0084459720</td>
</tr>
</tbody>
</table>

Notes: Supporting references and the status of the trials as at December 2010 are indicated.

Abbreviations: DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy.
directly impacting upon expression of dystrophin or its homologue, utrophin.

**Ready-to-use and combination therapies**

Corticosteroids have provided the best treatment option available to DMD patients to date and have also been used in limb girdle and BMDs\(^{21-23}\) despite significant side effects and the somewhat limited therapeutic value of these drugs. Corticosteroids stabilize muscle strength,\(^ {24,25}\) and in the short term, adverse effects were common but not clinically severe.\(^ {26}\) The use of corticosteroids in DMD is common and has been proposed as the ‘gold standard’, against which other treatments may be measured,\(^ {24}\) despite the uncertainty over the mode of action. The benefits of steroids in DMD in the short term have been validated through randomized clinical trials,\(^ {26,27}\) although dosage regimens are yet to be standardized. Significant impacts on health, quality of life, and health care costs in DMD were reported with the long-term use of deflazacort in uncontrolled cohort studies.\(^ {28-30}\) Treated boys had significantly better pulmonary and cardiac function and remained ambulant longer than untreated boys.\(^ {28}\)

The combination of steroid administration, respiratory and cardiac management, and physical care have led to dramatic improvements in quality of life, maintenance of function, and longevity in DMD.\(^ {31}\) DMD children treated by multiple interventions now have a possible life expectancy more than twice that of those born in the 1960s,\(^ {32}\) and the optimism that appropriate combinations of indirect treatments, with restoration, repair, or replacement of functional dystrophin, will dramatically alter the natural history of DMD is justified. With steroids now in common use, it is probable that muscular dystrophy patients being considered as subjects for clinical trials of investigational therapies, including molecular interventions, will be taking, or will have been treated with, corticosteroids. It is imperative to not only identify any contraindications to combination treatment, but also identify agents that might enhance the effects of other interventions.

Apart from corticosteroids, no other validated therapies for DMD have been available, and there is much interest in both nutritional supplements and ready-to-use pharmacological agents to reduce the relentless progression of the disease. The availability of the \(mdx\) mouse\(^ {33,34}\) and golden retriever muscular dystrophy (GRMD) dog\(^ {35,36}\) dystrophinopathy models has led to extensive preclinical studies on potential therapeutics. However, the lack of standardized experimental end points for the \(mdx\) mouse\(^ {37}\) and phenotypic variation in the dog model,\(^ {38}\) together with the high cost of maintaining the dogs, have made rigorous comparisons difficult. Evaluation of a number of compounds for the ability to limit the decline in muscle strength in \(mdx\) mice by Granchelli et al\(^ {39}\) indicated that prednisone, pentoxifylline, Tinset\(^ {40}\), insulin-like growth factor 1 (IGF-1), glutamine, glutamine plus alanine, and creatinine all improved muscle strength. Subsequent studies have failed to confirm some of these findings, particularly when treatment duration is extended. Implementation of validated preclinical assessment in \(mdx\) mice\(^ {37,40-42}\) that includes in vivo functional end points and histopathology and biochemical markers will facilitate more rigorous comparison of preclinical data from different laboratories and expedite evaluation in the \(mdx\) mouse, leading to effective clinical treatments for DMD.\(^ {42}\)

Although the \(mdx\) mouse is an appropriate ‘molecular’ dystrophinopathy model, its validity as a ‘clinical’ model for DMD, with its mild dystrophic pathology in muscles other than the diaphragm, is debatable. This has prompted the use of exercised \(mdx\) mice, which show a typical pattern of muscle weakness in vivo and exacerbated dystrophic pathology in heart.\(^ {43}\) Conductance to chloride in \(mdx\) muscle is impaired by chronic exercise and responds to treatment with compounds that stimulate regeneration (IGF-1 and steroids) or impede calcium-induced degeneration or inflammation (taurine and steroids).\(^ {40,41}\) Short-term beneficial effects on dystrophic pathology in \(mdx\) mice using a number of agents, including corticosteroids and arginine, have been reported, while chronic, continuous treatment with prednisone showed deleterious effects to skeletal and cardiac muscles,\(^ {44}\) and arginine leads to fibrosis of dystrophic heart and muscles.\(^ {45}\) Prednisolone treatment in \(mdx\) mice did not affect force loss during eccentric contractions or recovery of force following injury. These data emphasize a limitation of using mice as a preclinical model for DMD, because the increase in muscle strength in boys with DMD and taking prednisolone does not appear to occur via the same mechanism in dystrophic mice.\(^ {46}\)

Payne and colleagues\(^ {47}\) evaluated the potential benefit from creatine monohydrate, conjugated linoleic acid, alphalipoic acid, and beta-hydroxy-beta-methylbutyrate alone, in combination, and with prednisolone in exercised \(mdx\) mice and report evidence of therapeutic benefit from the four-compound combination therapy alone and together with corticosteroids.

Evidence supporting the essential role of functional ischemia in contraction-induced myofiber damage and a ‘two-hit’ mechanism in \(mdx\) mice was reported by Asai et al.\(^ {12}\)
The vasoactive drug tadalafil, a phosphodiesterase type 5 inhibitor, administered to mdx mice ameliorated muscle damage, and this has prompted a study of tadalafil in selected BMD patients (Table 1).

**Indirect approaches**

Skeletal muscle mass is dynamic, and under certain environmental cues and conditions, can be increased by different mechanisms or, conversely, reduced through activation of atrophy pathways induced by starvation, unloading, or disease. Hence, opportunities exist for intervention in muscular dystrophies by promoting the addition of new myonuclei into growing or regenerating myofibers, upregulating protein synthesis pathways, or suppressing inflammatory and atrophy pathways.

Myostatin (growth and differentiation factor 8 [GDF8]) has been identified as a major negative regulator of skeletal muscle mass, with myostatin-null animals showing a remarkable increase in mass of some muscles by 200%–300%. Myostatin is generated in an inactive form, and two separate proteolytic cleavages first remove the N-terminal signal peptide and then cleave the propeptide domain to produce the active form of the protein. Inhibition of the myostatin pathway represents a promising strategy to influence muscle mass and improves functional outcomes in muscle-wasting conditions (for review see Patel and Amthor48).

Follistatin is a natural antagonist of myostatin and other members of the transforming growth factor beta (TGF-β) superfamily, and overexpression of follistatin in mouse muscle leads to a profound increase in skeletal muscle mass (for review see Rodino-Klapac et al49 and Rose et al50). Disruption of the myostatin signaling pathway by overexpression of follistatin-related gene (FLRG),51 GDF-associated serum protein,52 and the myostatin propeptide51 resulted in substantially improved muscle function and increased mass in both normal and dystrophic tissue.52,53

Myostatin is not the only regulator of muscle growth, and it is apparent that other members of the TGF-β superfamily influence muscle mass. Activins are also members of the TGF-β family and are structurally related to myostatin. Both activins and myostatin signal through activin type II receptors (ActRIIA and ActRIIB) and their activities are regulated by follistatins and FLRG and by intracellular receptor-interacting proteins by novel mechanisms (for review see Tsuchida54). ACE-031 is a recombinant, soluble form of the activin receptor composed of the extracellular domain of the ActRIIB receptor and the human immunoglobulin Fc region.13 Preclinical studies in the mdx mouse13 and studies in normal volunteers were most promising, prompting further development of ACE-031 (see http://clinicaltrials.gov/ct2/show/NCT00755638). DMD patients are being recruited for a clinical study to determine if ACE-031 is safe and well tolerated in children and to establish an optimal dosage regimen with respect to safety and pharmacodynamic activity (see http://clinicaltrials.gov/ct2/show/NCT01099761). Lee and colleagues55 present evidence, suggesting that activin A may be one of the ligands that is regulated by follistatin and that it functions with myostatin to limit muscle mass.

Contraction-induced injury is a major contributing factor to the pathophysiology of muscular dystrophy, and therapies that attenuate this effect are being explored.46 IGF-1 variants mediate growth hormone signaling, and IGF-1 functions and regulation are complex and tissue specific. Mechano-growth factor (MGF) is an alternative splicing variant of IGF-1, and its expression is significantly increased in muscle, bone, and tendon following damage resulting from mechanical stimuli, and in the brain and heart following ischemia. MGF has been shown to activate satellite cells in muscle, resulting in hypertrophy or regeneration (for review see Dai et al57). Patients are currently being recruited for a study to determine whether IGF-1 therapy improves or preserves muscle function in DMD (see http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01207908).

Degradation of skeletal muscle extracellular matrix, inflammation, and fibrosis are the common pathological features in DMD. Although the underlying mechanisms remain poorly understood, strategies to ameliorate dystrophic pathology are being considered. Kumar and colleagues58,59 postulated that since expression of various matrix metalloproteinases is increased in dystrophic muscle, their suppression could dampen the extent of muscle pathogenesis in dystrophin deficiency. The 2-week-old mdx mice received three intraperitoneal injections per week over a 5-week period of batimastat (BB-94), a broad-spectrum peptide inhibitor of matrix metalloproteinases. Compared to sham-treated controls, the BB-94-treated mdx mice were found to have reduced necrosis, infiltration of macrophages, centronucleated fibers, and expression of embryonic myosin heavy chain. Deletion of the Mmp9 gene in mdx mice significantly improved muscle regeneration, pathology and function, and reduced muscle injury and inflammation. Pharmacological inhibition of Mmp9 activity also ameliorated skeletal muscle pathogenesis and enhanced myofiber regeneration in mdx mice.59

Oxidative stress and in particular, abnormal production of reactive oxygen species in mitochondria by monoamine...
oxidase have been identified as contributing to dystrophic pathogenesis.\textsuperscript{40} Thus, administration of antioxidants could, in theory, be beneficial. Pargyline, a monoamine oxygenase inhibitor, reduced reactive oxygen species accumulation along with a beneficial effect on dystrophic phenotype and muscle strength in mouse muscular dystrophy models, including \textit{mdx} mice.\textsuperscript{60} Idebenone was cardioprotective and improved exercise performance in the \textit{mdx} mouse\textsuperscript{41} and has been evaluated in DMD and Friedreich’s ataxia patients. Dorches and colleagues\textsuperscript{42} demonstrated that a green tea polyphenol blend and derived extracts could protect primary \textit{mdx} muscle cells from oxidative damage induced by hydrogen peroxide by scavenging H\textsubscript{2}O\textsubscript{2} and by improving the glutathione balance.

Most DMD patients develop clinically significant cardiomyopathy during the second decade of life, and currently, there are no effective therapies for the cardiomyopathy of DMD. Improvements in palliative care and management of respiratory function are extending the lives of patients. Strategies that restore dystrophin in skeletal muscles, but do not result in restitution of cardiac dystrophin expression, are likely to exacerbate this problem.\textsuperscript{63,64} Thus, there is an urgent need to address the emerging heart disease in DMD. Chronic infusion of a membrane-sealing poloxamer 188 (P188) to severely affected dystrophic dogs reduced myocardial fibrosis and prevented left ventricular remodeling.\textsuperscript{65} The P188 is Food and Drug Administration approved for short-term applications in humans and has the potential to halt the progression of dystrophic cardiomyopathy.

Although small molecules may be able to promote muscle growth and membrane stabilization or protect cells from oxidative stress, another approach relies on novel compounds to specifically upregulate expression of a homologous gene. Shortly after the dystrophin gene was identified, Love and coworkers\textsuperscript{66} identified an autosomal gene transcript that showed strong homology to dystrophin. Utrophin, a homologue of dystrophin expressed during fetal development, but restricted to the neuromuscular junction in mature muscle fibers, was subsequently shown to be able to replace dystrophin, if sufficiently overexpressed as a truncated utrophin transgene\textsuperscript{67} and by an adenovirus.\textsuperscript{68,69} Ubiquitous overexpression of utrophin in the \textit{mdx} mouse was nontoxic,\textsuperscript{70} prompting the search for compounds to reactivate utrophin expression. High-throughput screens identified several lead compounds that were refined and validated before entering a single-center, double-blind, placebo-controlled, single-dose escalation study, followed by a multiple-dose escalation study in healthy volunteers, sponsored by BioMarin. However, it was recently announced that development of BMN 195 (BioMarin Pharmaceutical Inc., Novato, CA) is being discontinued due to ‘pharmaceutical and pharmacokinetic challenges’. BioMarin concluded that other approaches to the upregulation of utrophin may be more feasible and are currently developing additional compounds to take forward to early human studies.

**Dystrophin restitution therapies**

It is perhaps not too surprising that therapies designed to modulate one or more of the downstream pathogenic pathways resulting from dystrophin deficiency confer only modest or transient benefits. However, such approaches do have merit. Glucocorticoids confer a measurable but transient benefit by delaying the decline in muscle function and are currently regarded as standard in the management of DMD.\textsuperscript{24,25,32} Dystrophin plays a pivotal role in forming a stabilizing link between the actin cytoskeleton and the dystrophin-associated complex of proteins embedded in the sarcolemma, and consequently, the restitution of dystrophin with some degree of function is likely to offer more tangible benefits to DMD muscle.

Apart from dystrophin expression mediated by gene or cell therapies, two distinct strategies to overcome dystrophin mutations have shown great potential in preclinical studies. More than 2 decades ago, particular antibiotics of the amino-glycoside family appeared to promote codon misreading during eukaryotic messenger RNA (mRNA) translation and allow read-through of nonsense mutations (for review see Finkel\textsuperscript{71}).\textsuperscript{72} The use of gentamicin, one of the first compounds reported to induce read-through of nonsense mutations, provided promising data when applied to nonsense mutations in the cystic fibrosis transmembrane regulator gene.\textsuperscript{73} It is essential that codons encoding amino acids and normal termination codons are correctly processed, as accumulation of mistranslated proteins could be catastrophic. The discrimination of a premature stop codon from a normal stop codon was considered possible, determined by the context of surrounding bases and the fourth base of the termination codon.

Potential renal and otic adverse effects associated with gentamicin exposure are well documented, prompting the search for other compounds to specifically induce read-through of nonsense mutations. PTC-124 (ataluren; PTC Therapeutics, South Plainfield, NJ) was identified as the lead compound reading through the UGA termination codon. This compound was reported to restore some dystrophin expression in human and \textit{mdx} mouse cells, carrying nonsense mutations in the dystrophin gene. Subsequent experiments
indicated that substantial expression was induced after 4 weeks of treatment in the mdx mouse,\textsuperscript{17} with a combined intraperitoneal and oral administration regimen proving most effective.

With this promising preclinical data, and additional phase I studies in healthy volunteers, a double-blind, placebo-controlled phase IIb trial was initiated to evaluate efficacy and safety over a 48-week period. Participants received either a low dose of ataluren (10, 10, and 20 mg/kg/day), a high dose (20, 20, and 40 mg/kg/day), or placebo. Despite being very well tolerated, with no participants discontinuing the treatment due to adverse effects, the primary end point of change in the 6-minute walk test failed to reach statistical significance during the trial. Ongoing studies of ataluren in DMD patients have been discontinued for the time being, but additional analysis is underway in patient subgroups.

Whatever the final outcome, these studies have made a major contribution to the design and evaluation of trials for DMD therapies and set important efficacy outcomes that are pivotal for subsequent DMD studies. Ataluren evaluation will continue for other conditions, including cystic fibrosis and hemophilia, and this seems most appropriate, considering that these conditions may benefit from modest increases in the target protein, whereas greater expression of dystrophin will be necessary for physiological and clinical improvement.

The mode of small-molecule screening used by researchers to identify read-through compounds has come under scrutiny. Auld and colleagues\textsuperscript{74,75} report that PTC-124 increased the firefly luciferase read-out by posttranslational stabilization rather than read-through of the termination codon. Clearly, additional studies are needed to clarify this issue. Nonsense mutation read-through holds great promise for patients afflicted by a wide range of inherited disorders caused by nonsense codon mutations.

Paradoxically, despite the potentially adverse side effects associated with long-term gentamicin administration and the first short-term gentamicin study failing to detect any clinical benefit,\textsuperscript{76} Malik and colleagues\textsuperscript{18} recently published data from a 6-month open-label trial and unequivocally demonstrated that gentamicin could indeed restore some dystrophin expression in DMD patients carrying nonsense mutations. Two cohorts received daily infusions of gentamicin (7.5 mg/kg) for 2 weeks, and the serum creatine kinase was reduced to about 50% in the cohort of DMD individuals with nonsense mutations, whereas there was no change in the cohort of DMD participants whose genes had been inactivated by frameshifting deletions. Two additional cohorts received the low dose (7.5 mg/kg) either weekly or biweekly for 6 months, and dystrophin levels were increased, with the highest levels reaching up to 15% of normal levels. In this study, there was no apparent influence of the different premature stop codon sequences on read-through efficiency, and one patient appeared to raise antibodies to the novel dystrophin protein. This study both justifies and highlights the need for continued screening for compounds to safely induce read-through of premature termination codons. During this study, one participant in the cohort receiving biweekly gentamicin infusions inadvertently received four doses that were 125% of that intended. He suffered transient high-frequency hearing loss and was withdrawn from the study due to protocol requirements.\textsuperscript{18}

The unequivocal demonstration of dystrophin restoration in some DMD cases in response to gentamicin treatment has prompted resurged interest into other compounds, which are more efficient at nonsense mutation read-through, as well as having a lower toxicity profile. Nudelman and colleagues\textsuperscript{77} reported in vitro studies of read-through of several different mutations using the aminoglycoside 2 NB54, which was subsequently shown to be far less toxic than gentamicin.

**Splice intervention therapy**

**Preclinical studies**

A DMD therapeutic strategy currently gaining considerable momentum is antisense oligomer (AO)-induced splice manipulation, where a DMD-causing mutation is bypassed by targeted exon removal or ‘exon skipping’. One or more exons flanking a frameshifting exon rearrangement may be removed to restore the reading frame, or an exon carrying a nonsense mutation can be masked from the splicing machinery so that it is removed from the mature gene transcript. Different mutations across the dystrophin gene will require specific exon-skipping strategies, necessitating potential scores of oligomers. Unlike experimental therapies being evaluated to upregulate a homologous gene\textsuperscript{78–80} or read-through premature stop codons\textsuperscript{15,17,71} (for review see Nelson et al\textsuperscript{81}), exon skipping must be regarded as a personalized therapy because of the spread of different mutations across the dystrophin gene, requiring different exon-skipping strategies. DMD is considered an ‘orphan disease’, based on the criteria that there are < 200,000 affected individuals in the USA, and there is little incentive to the private sector to develop and market specific therapies. Bringing any drug to the clinic is costly and challenging, and orphan disease status provides incentives to develop treatments for rare conditions. However, when one considers that scores of different AOs would be
needed to treat DMD patients with different mutations, the challenges seem insurmountable. Fundamental changes to the drug development pipeline will have to be implemented before exon-skipping therapy can become a reality for all amenable DMD mutations.

There was a flurry in interest in the use of short, chemically synthesized oligomers to modify gene expression after Zamecnik and Stephenson described the use of an oligodeoxribonucleotide (ODN) to suppress viral replication. Many subsequent reports of gene suppression were eventually attributed to nonsequence-specific effects, often relating to the oligomer backbone. However, as new generation oligomer chemistries were developed and experimental design was refined and became more rigorous, additional methodologies to manipulate gene expression using AOs were developed, including translation suppression, gene silencing and modification of pre-mRNA splicing (for review see Bennett and Swayze).

Manipulation of pre-mRNA splicing can alter gene expression by downregulating the transcript or induce specific isoforms and suppress abnormal or cryptic splicing. A major advantage in assessing changes in pre-mRNA processing is the appearance of a novel transcript, which may be monitored in a positive assay by reverse transcriptase polymerase chain reaction (RT-PCR), or detection of an induced protein by Western blotting. Gene suppression by RNaseH, silencing, or translational blockade can be more problematic to assess because the disappearance or reduction in abundance of a transcript or protein is measured in a negative assay. Absence of evidence, the decreased abundance of a gene transcript or product, is not necessarily irrefutable evidence of absence, as off-target effects of the oligomer may compromise global transcription or translation.

One surprising observation was the high proportion of splice-switching AOs, approximately two-thirds, that did induce some degree of exon skipping. Approximately, one-third of splice-switching AOs initially designed failed to induce any detectable effect on dystrophin pre-mRNA processing and may be considered as ‘unintentional’ negative controls, despite being complementary to the dystrophin pre-mRNA.

An appropriately designed splice-switching oligomer should induce specific exon skipping and generate a novel mRNA transcript in a dose-dependent manner. If the loss of the targeted exon bypasses a protein-truncating mutation, a new protein should be generated. Mindful of omissions in early AO design, a series of splice-switching oligomer controls, including random, scrambled, unrelated, and sense strand sequences, have been evaluated to confirm that any detectable changes in gene expression were sequence specific and not attributable to the oligomer chemistry or nonsequence-specific effects. However, the concept of exon skipping is now so well established that the majority of recent reports on dystrophin splice switching do not include random, scrambled, or sense oligomer sequences as negative controls.

There is little doubt that targeted exon skipping, assuming it can be induced at adequate efficiency in dystrophic muscle, would reduce the severity of most cases of DMD. The reading frame rule holds true in the majority of dystrophin mutations, with any discordance between the genotype and phenotype normally resolved by studying the dystrophin mRNA and identifying secondary effects on RNA processing as a consequence of the mutation. Ginjaar and colleagues identified a nonsense mutation in dystrophin exon 29 in one BMD family that induced different levels of exon skipping in three affected boys. The phenotypes in this family varied from healthy to severely affected and appeared to correlate with the amount of exon 29 skipping, since the loss of this exon does not disrupt the reading frame and removes the mutation. Characterization of the dystrophin gene structure in mildly affected or asymptomatic BMD individuals provides templates for functional dystrophin isoforms and establishes which regions of the protein are partially redundant. Furthermore, exon skipping has been shown to occur naturally, as evidenced by the presence of revertant dystrophin-positive fibers in many DMD individuals and mouse and canine models of muscular dystrophy. Although occurring at a frequency too low to be of any substantial clinical benefit, these fibers may contribute to the immune tolerance of induced BMD-like dystrophin isoforms.

The successful implementation of exon skipping to treat DMD will require careful optimization of oligomer design, evaluation, and delivery, and then perhaps even more challenging will be establishment of a product development pipeline to bring new compounds to the clinic.

**Splice-switching oligomers**

**Sequence selection**

The application of AOs to induce targeted dystrophin exon skipping was first reported by Takeshima and colleagues. After detailed characterization of an intronic deletion of 52 bp in dystrophin exon 19, which left the acceptor and donor splice sites intact but resulted in the loss of the entire exon. In a series of experiments using different oligomer chemistries and in vitro assessment systems, specific removal
 exon 19 was induced from the dystrophin mRNA in artificial constructs, lymphoblastoid cells, and later in human and mouse cells. 

Early splice-switching studies in the mdx mouse model of muscular dystrophy targeted the obvious splice sites at the intron 22:exon 23 (acceptor or 3') and exon 23:intron 22 (donor or 5') splice sites, as these motifs offered easily defined and crucial motifs involved in pre-mRNA processing. Although the donor splice site proved to be a more amenable target for exon 23 skipping, the acceptor site was unresponsive, indicating a limitation to directing AOs to obvious splice motifs. When designing AOs to other dystrophin exons, we chose an empirical approach, starting with the obvious donor and acceptor splice sites and then intraexonic motifs, potential exon splicing enhancers that are predicted binding sites for the SR proteins involved in exon definition.

Several hundred AOs have now been designed to the dystrophin pre-mRNA (Wilton and Fletcher, unpublished data), and the mechanisms by which antisense sequences influence exon recognition and splicing have still not been clearly defined. Aartsma-Rus and colleagues suggest that intraexonic sequences provide better targets that splice sites and proposed that the higher GC content of the exons offered better thermodynamic properties. These authors concluded that 'when designing AOs to induce exon skipping in DMD, targeting exon sequences is most likely to result in an effective AO. There are, however, exceptions, and of course, further optimization of the AO is often required'.

It is unlikely that a simple formula or set of thermodynamic parameters will guarantee design of effective splice-switching AOs, as there is considerable variation in levels of induced exon skipping, both within and between exons. AO length and target sequence were identified as important parameters in AO design, while Wee and colleagues reported that cotranscriptional pre-mRNA folding influenced AO-induced dystrophin exon skipping. Secondary structures were predicted, and the frequency and localization of base-paired nucleotides in an AO target site correlated with AO performance of 94% of 176 previously reported sequences.

In a comparative study of several different AOs to induce human dystrophin exon 51 skipping, targeting the donor splice site proved ineffective, despite extensive micro-walking and variation in AO length. The exons that were difficult to remove using single AOs could often be excised by select AO combinations, suggesting that many factors are involved in exon recognition and splicing. Clearly, an oligomer preparation that can induce pronounced exon skipping in cultured cells at 5 nM will be more effective than an oligomer that promotes weak exon removal after transfection at higher concentrations. Clinical application will require AOs that are effective at low dosages, thus reducing treatment costs and the likelihood of adverse effects, and to date, in vitro evaluation has been widely used to select AO sequences for dystrophin exon skipping. It was recently reported that in vitro evaluation of novel AOs reflected in vivo exon-skipping activity, at least in the mouse. Despite strong homology in the dystrophin genes of human, mouse, and dog, directing AOs to the pre-mRNA motifs does not necessarily induce comparable exon skipping. Although the mouse dystrophin exon 23 was readily removed after targeting the donor splice site, the human equivalent was unresponsive. In this study of comparable exons in human and mouse exon skipping, only one-third of targets were optimal in both species. Similarly, Saito and colleagues reported that motifs targeted to excise canine dystrophin exons 6 and 8 were also effective in cells from a DMD patient missing exon 7, although it should be noted that there was a difference in removal of exon 9 between the two species.

**Evaluation and quantitation of AO-induced exon skipping**

In order to assess AO efficacy, it will be important to accurately determine changes in dystrophin expression and restoration of the induced dystrophin isoform synthesis. Ultimately, it will be the amount of dystrophin expression in vivo that will alter the progression of DMD, rather than experimentally enhanced exon skipping assessed by RT-PCR. We previously reported that manipulating RT-PCR amplification conditions exaggerates apparent exon skipping and does not reflect protein levels. By increasing the cycle number and minimizing the length of the amplicons, 25% of the transcripts in treated mdx samples appeared to be missing the target exon, yet no dystrophin was detected by Western blotting.

A series of techniques to quantify exon skipping levels by RT-PCR were reported by Spitali and colleagues and indicated that quantification of small primary PCR products using a bioanalyzer or densitometric analysis generated data close to that from a digital array. Perhaps more relevant to the assessment of exon skipping and dystrophin-isoform restoration in preclinical and clinical studies is the quantification of protein levels in muscle biopsies based upon digital capture of immunofluorescently labeled sections.
This method will be of great value in allowing comparative quantification of sarcolemmal proteins, as it allows both abundance and localization of the protein to be monitored. This will be useful in assessing experimental therapies where only partial restoration of the protein may occur. Efforts are now under way to ensure standardized testing in order that data from different clinical trials and different centers can be compared and directly evaluated.117 This will be relevant for not only exon skipping, but also other therapies designed to supplement, compensate for, or replace dystrophin.

**Oligomer chemistries**

Several different oligomer chemistries have demonstrated some capacity to redirect dystrophin pre-mRNA processing, including DNA oligomers on a phosphorothioate backbone (ODN),102 locked nucleic acids,118 ethylene nucleic acids,119 peptide nucleic acids,92 RNA-like analogues with 2′-O-modified bases on a phosphorothioate backbone (2′-OMeAO), and phosphorodiamidate morpholino oligomers (PMOs).118,120,121 Each oligomer chemistry has specific advantages and limitations and, to date, three different clinical trials have been reported using ODN, 2′-OMeAO, and PMOs.19,20,122 Active and recently completed clinical trials for DMD listed at http://clinicaltrials.gov are summarized in Table 1.

**Delivery**

All nucleic acid therapies are hampered to some extent by limitations of delivery and distribution, and in the case of DMD, it is further complicated by the need to deliver therapeutic levels of the oligomer to skeletal (30% of total body mass), cardiac, and smooth muscles and other tissues. AO design and evaluation in vitro require transfection with either high concentrations of the compound, as uptake is poor, or the use of a delivery agent to enhance delivery. A large number and variety of reagents have been used to deliver charged AOs in vitro, including cationic liposomes,87,88,104 PEI,123 copolymers,124,125 cationic nanoparticles,126 or polymersomes.127 Uncharged PMOs are largely ineffective in vitro unless applied at high concentrations with scrape loading,128 although delivery can be greatly enhanced with the use of a sense strand leash and a cationic lipoplex121 or coupling to cell-penetrating peptides (CPPs)129–132 or an octa-guanidine dendrimer.134,135 Although many delivery reagents have facilitated AO uptake in vitro, most will not be applicable to preclinical evaluation or in the clinic. Fortunately, we observed that uncomplexed PMOs were efficiently taken up in the dystrophic muscle after direct intramuscular injection and restored robust dystrophin expression around the injection site.120

**Animal models**

Exon skipping has now been applied to several animal models, most commonly the mdx mouse that carries a nonsense mutation in exon 23. Although this is not a good clinical model for DMD, it has allowed numerous studies assessing oligomer sequences and chemistries,87,88,112,120,129,133,136–138 modifications to enhance PMO uptake,130–132,134,139–141 delivery routes,142 and regimens.130,139,143,144 Other mouse models studied to date include the mdx4Cv mouse (nonsense mutation in exon 53 that requires removal of exons 52 and 53)148 and the mdx52 mouse missing exon 52.90 These latter animal models are perhaps more relevant than the original mdx mouse model, since the mutations occur in the major human deletion hotspot region of the dystrophin gene.

The ‘humanized’ mouse146 contains a complete copy of the human DMD gene integrated into chromosome 5 and has been promoted for the preclinical screening of human-specific oligomers and comparison of different AO sequences and chemistries. While the mdx mouse does not reflect clinical severity of DMD and the humanized mouse has a human dystrophin gene processed with rodent splicing machinery, perhaps the most appropriate and challenging animal model in which to test exon skipping as a therapy is the dko mouse.147 Although the utrophin or dystrophin null animals appear normal, especially during the early life, the loss of both genes results in animals with severe muscle wasting, and the dko animals typically die by the age of 15 weeks. Repeated, weekly, intraperitoneal administration of a PMO conjugated to a cell penetrating peptide (CPP–PMO), starting a few days after birth, was found to prevent onset of pathology.148 Treated animals remain normal in appearance at 1 year of age (Goyenvalle, personal communication), demonstrating that the restoration of a BMD-like dystrophin isoform in this model is highly functional.

In vivo studies using the GRMD canine model were reported by Yokota and colleagues149 after systemic administration of substantial amounts of a PMO cocktail to excise exons 6 and 8/9 to restore the reading frame around the exon 7 frameshift. This work was particularly encouraging in that large amounts of PMO were administered without any obvious adverse effects, and dystrophin was expressed throughout the body. Like other studies using similar dosages of uncomplexed PMOs in the mouse,120,136 dystrophin expression in the heart was low or undetectable, presumably reflecting limitations of uptake; however, systemic
administration of a single dose of an uncomplexed PMO at 3 g/kg resulted in dystrophin restitution in skeletal and cardiac muscles in the mdx mouse, without clear toxicity.144 Efficient AO delivery into many tissues, including the heart, may also be addressed by the use of specific CPPs coupled to the PMO.130 These researchers recently reported long-term prevention (7 months) of cardiac dysfunction after early treatment with a CPP–PMO.139 Other CPPs for enhanced PMO delivery have been reported,141,150,151 and this promises to be a most active area of research. Although many CPPs examined to date greatly enhance PMO uptake, concerns remain regarding the clinical applicability of these compounds due to potential adverse effects.

Clinical trials
The first splice-switching clinical trial in a 10-year-old, nonambulant DMD patient used systemic administration of a 31mer ODN on a phosphorothioate backbone, designed to excise exon 19 and restore the reading frame around the DMD-causing exon 20 deletion.152 Although dystrophin exon 19 skipping was demonstrated in RNA extracted from lymphocytes after the infusion, the dystrophin staining was equivocal, and Western blot data was not presented. The inconclusive dystrophin staining in this n = 1 study may be attributed to several factors, including a readily available but less-than-optimal oligomer chemistry or insufficient dosage and duration of treatment to restore detectable dystrophin expression. Although this trial did not generate unequivocal dystrophin expression or demonstrate any benefit to the recipient, there were no adverse effects, and the compounds were reported to be well tolerated.152 ODNs are typically used to downregulate gene expression through induction of RNaseH, a ubiquitous enzyme that degrades the RNA strand of an RNA:ODN duplex.153 We previously demonstrated that ODNs induce dystrophin exon 19 skipping,156 but only after in vitro transfection at much higher concentrations than those used for the same sequence prepared as a 2OMe AO or PMO. Although RNaseH is found in the nucleus where the AO splice switching occurs during cotranscriptional processing, presumably once the target exon is excised from the mature mRNA, that transcript would no longer be susceptible to RNaseH degradation.

In contrast, proof-of-concept studies using AOs of 2OMe or PMO chemistries conclusively demonstrated that induced exon 51 skipping restored the dystrophin reading frame around amenable DMD deletions and restored dystrophin expression after localized delivery. Van Deutekom and colleagues19 reported the administration of PRO051, a synthetic 20mer composed of 2′-O-methyl modified bases, on a phosphorothioate backbone designed to excise exon 51 during dystrophin pre-mRNA processing in patients with deletions of exon 50, 48–50, 49–50, and 52. After injection of 0.8 mg of PRO051 into the tibialis anterior muscle, a biopsy was taken 28 days later and found to contain a high proportion of dystrophin-positive fibers. It was reported that accurate quantification of skipping efficiencies and the meaningful correlation between levels of RNA and protein were not possible since high-sensitivity RT-PCR conditions were employed. Nevertheless, results were sufficiently encouraging to proceed with systemic administration of PRO051, delivered subcutaneously at a weekly dose of 6 mg/kg for several months. Tantalizing unpublished data has been reported, indicating low-level, widespread dystrophin expression after 12 weeks of treatment, and peer-reviewed published data is eagerly awaited.

We proposed that the PMO chemistry is better suited for clinical application for induced exon skipping because of the sustained exon skipping in vivo.120,129 In addition, PMOs, developed to suppress translation,154 have been developed as antivirals,155,156 and in a number of clinical trials, they have shown an excellent safety profile.157,158

Analysis of DMD deletion frequency has indicated that exclusion of exon 51 will benefit the greatest number of DMD patients, and this exon was selected as the lead target exon for therapeutic exon-skipping trials. After comparative evaluation of several PMO sequences, including PRO051, one was selected for further preclinical development.110 This compound, licensed through the University of Western Australia to AVI BioPharma (Bothell, WA) was designated AVI-4658 and used in a single-blind, placebo-controlled, dose-escalation study, sponsored by the MDEX consortium, to confirm proof-of-concept that DMD mutations could be bypassed using a PMO.20 The MDEX trial structure differed from the PRO051 study in that low (0.09 mg) or high (0.9 mg) doses were administered into the extensor digitorum brevis of one foot, while a sham (saline) injection was applied to the contralateral muscle. An open biopsy of both muscles was performed 3–4 weeks later, and samples were subjected to RT-PCR and immunohistochemical studies. There was a clear dose response. Dystrophin exon 51 skipping was detected in the muscle receiving the low dose, but no protein was evident under preestablished testing conditions. At the high dose, exon 51 skipping was readily detected by RT-PCR in test biopsies from all participants, and there was unequivocal dystrophin expression as determined by Western blotting and immunofluorescent staining.20
The preliminary results from the AVI-4658 study were sufficiently encouraging to commence dose-escalating systemic administration in DMD participants, whose genomic deletions would have the reading frame restored by exon 51 exclusion (Table 1). Participants were divided into 6 cohorts, each receiving 12, once-weekly, intravenous infusions of AVI-4658 at doses of 0.5, 1, 2, 4, 10, and 20 mg/kg (Muntoni, personal communication). Data indicate that exon skipping was induced in dose-dependent manner, and apart from one individual receiving 2 mg/kg who was found to be a ‘strong’ responder, all other participants receiving up to 4 mg/kg had transcripts missing exon 51, but protein was not detected. All boys receiving 10 or 20 mg/kg showed strong exon skipping by RT-PCR, and dystrophin expression was readily detectable in three out of four boys in each cohort. One boy from each of these cohorts had considerably higher dystrophin expression than the others who were deemed to be ‘strong responders’. In summary, seven patients had unequivocally increased dystrophin expression after comparing pre- and posttreatment biopsies (Muntoni, personal communication). An extension to the MDEX study has not been offered to the participants at this stage (see http://www.actionduchenne.org/duchennepedia/article/229/recent-avi-4658-trial-results-), which is unfortunate considering the positive outcomes in terms of dystrophin expression at the higher doses of AVI-4658. One of the most attractive features of the PMO chemistry is that these compounds appear to be very well tolerated, with no PMO-related effects on cardiovascular, respiratory, global neurological, renal, or liver parameters after administration of the maximum feasible dose (320 mg/kg) in cynomolgus monkeys. Both the mouse and the canine models of muscular dystrophy have received different PMOs at substantial dosages of 200 mg/kg in the GRMD animal and 3 mg/kg in the mdx mouse. Dystrophin expression was restored without overt toxicity; however, the consequences of long-term exposure at these dosages are yet to be established.

Furthermore, while high PMO doses may offer a rapid restitution of dystrophin synthesis, it is most unlikely that, even if these high doses were to prove safe and tolerable, such amounts would be financially sustainable at this time. Until recently, patent protection on morpholino synthesis restricted the production of Good Laboratory Practice-compliant PMOs, and production facilities at this point in time are limited. Potential manufacturers would be reluctant to commit to major capital expenditure on expanded production facilities, especially when there is no guaranteed demand. Although the PMO exon-skipping trials are generating exceedingly positive data, no obvious clinical benefit has yet been conferred to any participant, and future requirements for these compounds are uncertain at this time.

Nevertheless, PMO production is a technical issue. Those involved in early molecular biology experiments may recall the high cost of oligomers used as gene-specific probes or for PCR. Not only has the quality and reliability of production increased, but also costs have decreased by orders of magnitude. In some respects, there are many similarities to the development of penicillin, where the first reported US patient treated for streptococcal septicemia used one half of the total available supply produced by Merck & Co (Whitehouse Station, NJ). At that time, penicillin was priceless, and 15 months later, there was only enough material to treat 10 patients (see http://www.lib.niu.edu/2001/iht810139.html). However, in response to demand to treat casualties from World War II, there was a concentrated effort to increase production, and by 1946, the cost was reported as 55c per dose.

**Concluding remarks**

In treating DMD, significant long-term benefit can only be conferred by dystrophin restitution, and of all the novel experimental therapies to treat DMD discussed here, only gentamicin administration and oligomer-induced exon skipping have resulted in readily detectable dystrophin expression in DMD patient’s muscle. Although gentamicin treatment has produced promising results, its use can be accompanied by significant side effects that may limit long-term administration. Nonsense mutation read-through is restricted to the 10% of cases caused by premature termination codons, but it is potentially applicable to a similar percentage of a wide range of inherited disorders. This data, together with the broad applicability of read-through compounds, would be expected to accelerate development of these drugs and the search for compounds with improved safety profiles.

The promising clinical data from the DMD exon-skipping trials is anticipated to drive further development in this field, particularly for the relatively small number of splice-switching compounds required to treat the more common DMD mutations, but many compounds must be designed and optimized to address all amenable mutations, so as not to disadvantage DMD patients with the added misfortune of having rare mutations. Although the greatest benefit of dystrophin restitution will undoubtedly be derived from early treatment in younger patients, the use of emerging ‘combination’ therapies that aim to preserve muscle or promote muscle repair in muscular dystrophies and restore protein expression may well deliver functional improvements in older patients.
Acknowledgments
The authors acknowledge funding from National Institutes of Health USA, the Muscular Dystrophy Association of the United States of America, Muscular Dystrophy Western Australia, the National Health and Medical Research Council of Australia, the James and Matthew Foundation, the Gavriel Meir Trust and the Medical and Health Research Infrastructure Fund, Western Australia.

Disclosure
The authors report no conflicts of interest in this work.

References


